RecruitingNCT06600906

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer

Sponsor

University of California, San Francisco

Enrollment

70 participants

Start Date

Oct 1, 2024

Study Type

OBSERVATIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Metastatic Pancreatic Ductal Adenocarcinoma Locally Advanced Pancreatic Ductal Adenocarcinoma

Summary

This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). MRI is a standard scan that helps doctors see tumors, organs, tissue, and bone. Standard contrast agents (e.g., gadolinium) are sometimes used to help make the scan images brighter, or easier to see. Hyperpolarized carbon-13 pyruvate is an experimental contrast agent that is different from standard MRI contrast in that it provides information on how a tumor processes nutrients. Hyperpolarized carbon-13 pyruvate MRI scans may work better than MRI with standard contrast agents in predicting how PDA tumors respond to treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialised MRI technique called hyperpolarized carbon-13 MRI — which can show how tumour cells use energy in real time — to try to predict how well pancreatic cancer patients will respond to their chemotherapy treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) confirmed by biopsy or cell analysis - Your cancer is locally advanced or has spread to other organs (metastatic) - You have at least one measurable tumour in the abdomen at least 1 cm in size - You are in reasonably good health (ECOG performance status 0, 1, or 2) **You may NOT be eligible if...** - You are unable to have an MRI (for example, you have a pacemaker or certain metal implants in your head) - You have poorly controlled high blood pressure (over 170/110) - You have significant heart failure (Class III or higher) - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHyperpolarized 13C-Pyruvate

Given intravenously (IV)

PROCEDUREComputed tomography (CT)

Undergo CT imaging

PROCEDUREMagnetic Resonance Imaging (MRI)

Undergo MRI imaging

Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06600906

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

NCT072142981 location

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121279 locations

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

NCT071570334 locations